S-phase kinase-associated protein 2 (Skp2), a member of the F-box family, is the substrate recognition subunit of the Skp1-Cullin-F box protein (SCF) E3 Ubiquitin ligase complex, which mediates ubiquitination of proteins targeted for proteasomal degradation [@b1]. Skp2 recognizes and causes the degradation of some inhibitory proteins, such as p27/Kip1 and p21/Cip1, leading to cell cycle progress. In cancer cells, overexpression of Skp2 results in the dysfunction of cell cycle arrest. If so, cancer cells with DNA damage cannot halt the progress of cell cycle and trigger DNA repair or apoptosis pathways, eventually inducing genomic instability. Therefore, Skp2 is commonly overexpressed and associated with poor prognosis in a variety of human cancers, including colorectal cancer, gastric cancer, breast cancer, and oral cancer[@b2]. Nasopharyngeal carcinoma (NPC), the malignant dysplasia of nasopharyngeal epithelia, is an epidemic malignancy in South China, resulting from the unlimited proliferation of nasopharyngeal epithelia. Due to the essential role of Skp2 in progressing cell cycle, Skp2 level may be associated with NPC development. However, the prognostic role of Skp2 in NPC cases from this region has not been investigated.

Current evidence suggests that only a small fraction of cells in a tumor are responsible for its initiation, growth, and development[@b3], and such cells have been designated cancer stem cells or cancer stem-like cells (CSCs)[@b4]. Most importantly, CSCs usually express membrane transporters like ABCG2[@b5] and ABCB5[@b6], which can efflux chemotherapeutic agents out of the cell membrane, leading to chemoresistance. CSCs can also acquire the capacities of migration and invasion via epithelial-mesenchymal transition[@b7],[@b8], therefore resulting in cancer metastasis. In addition, many studies have shown that overexpression of CSC markers, such as ALDH1 in breast cancer[@b9] and CD133 in colorectal cancer[@b10], is correlated with poor prognosis. Thus, there is a strong basis for implicating CSCs in tumor development and progression. The side population (SP), a small population of cells distinguished by their ability to efflux the DNA binding dye Hoechst 33342 out of the cell membrane, have been reported to exhibit stem cell characteristics and enrich the stem cell-like population in cancer[@b5],[@b11],[@b12]. Indeed, CSC-like SP cells have been isolated and identified in human NPC cell lines, including CNE-1 and CNE-2[@b13]. Since our previous study has indicated that genomic instability, possibly initiated by Skp2 overexpression, can induce cancer stem cells[@b14], we hypothesized that Skp2 may play a potential role in NPC stem cells. In this study, we provided evidence that Skp2 overexpression is associated with poor prognosis of NPC in South China, and this negative relationship is likely due to a Skp2-mediated increase in the SP fraction size.

Materials and Methods {#s2}
=====================

Patients {#s2a}
--------

A total of 150 patients who were pathologically diagnosed with NPC and undergone primary treatment at Sun Yat-sen University Cancer Center between October 1999 and December 2000 were recruited. Tissue samples collected from each patient during pretreatment biopsy and clinical follow-up were retrieved from Department of Pathology, Sun Yat-sen University Cancer Center.

NPC tissue microarray and immunohistochemical staining (IHC) {#s2b}
------------------------------------------------------------

A tissue microarray of 150 cases was constructed by a pathologist from the Department of Pathology, Sun Yat-sen University Cancer Center. Two tissue cylinders (1.0 mm in diameter) were punched from each specimen. For IHC, tissue microarray blocks were cut into slides at 3-µm thickness. The slides were deparaffinized in xylene, rehydrated through graded alcohols to water, heated in boiled EDTA buffer (pH 8.0) for 10 min, and cooled naturally to room temperature. They were subsequently immersed in 3% hydrogen peroxide solution for 10 min to remove endogenous peroxidase activity, blocked with 10% goat serum at room temperature for 30 min, and then incubated with mouse anti-Skp2 (1:40, Invitrogen) overnight (about 16 h) at 4°C. After being washed with PBS, the slides were incubated with secondary antibody (Two-step anti-rabbit/mouse universal immunohistochemistry kit, Dako) at room temperature for 30 min and then developed with DAB for 6.5 min. Slides were counterstained with hematoxylin. PBS was used to replace the primary antibody as a negative control. The expression of Skp2 was evaluated independently by two pathologists blinded to the clinical and follow-up data. Cells that had brown-yellow granules in the nuclei were defined as positive, whereas cells without brown-yellow granules in the nuclei were defined as negative[@b15].

Cell culture and siRNA transfection {#s2c}
-----------------------------------

NPC cell lines CNE-1 and CNE-2 were obtained from the State Key Laboratory of Oncology in South China. Cells were cultured in DMEM containing 10% fetal bovine serum at 37°C in a humidified atmosphere containing 5% CO~2~. Transient transfection of 50 nmol/L of Skp2 small interfering RNA (siRNA) or scrambled siRNA (negative control) was performed using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer\'s instruction. The cells with out siRNA transfection were used as empty control. Both Skp2 siRNA and scrambled siRNA were synthesized by the Ribobio Company (Guangzhou, China). The sequences of the Skp2 siRNA were 5′-GGUAUCGCCUAGCGUCU-GAdTdT-3′ for sense primer and 5′-UCAGACGCUAGG-CGAUACCdTdT-3′ for antisense primer. The sequences of scrambled siRNA were 5′-UUCUCCGAACGUGUCAC-GUTT-3′ for sense primer and 5′-ACGUGACACGUUCG-GAGAATT-3′ for antisense primer.

Western blot assay in NPC cells {#s2d}
-------------------------------

The Western blotting procedure was described previously[@b14]. Briefly, cells were harvested 48 h after siRNA transfection and lysed in a lysis buffer containing a cocktail of protease inhibitors. After centrifugation at 15 000 × *g* for 15 min at 4°C, supernatants were collected, mixed with dithiothreitol and used for the Western blotting. Equal amounts of protein extract were electrophoresed in 10% SDS-PAGE gels and then transferred to nitrocellulose membranes. The membranes were blocked with 3% non-fat milk at room temperature for 1 h, incubated with anti-Skp2 (1:1000, Invitrogen) overnight at 4°C, and incubated with the secondary antibody at room temperature for 1 h. After washing the blots with TBST, proteins were visualized by chemiluminescence.

Colony formation assay in NPC cells {#s2e}
-----------------------------------

Colony formation assay was performed according to the procedure reported previously[@b14]. Briefly, 36 h after siRNA transfection, cells were trypsinized, resuspended as single cells, and plated to 6-well plates with 100 cells per well. After 10 days, the colonies were fixed with methanol and stained with crystal violet. Colonies with more than 50 cells were counted under the microscope. The cloning efficiency was calculated by the formula: colony formation rate = (clone number / inoculation cell number) × 100%.

Side population detection in NPC cells {#s2f}
--------------------------------------

Side population was detected according to the procedure reported previously[@b14]. Briefly, 48 h after transfection, the cells were harvested and resuspended in DMEM containing 2% FBS at a concentration of ∼1 × 10^6^ cells/mL. Hoechst 33342 (Sigma-Aldrich), a DNA-binding dye, was added at a final concentration of 5 µg/mL, and the suspension was incubated in dark at 37°C for 1.5 h with interval mixing. Another subset of cells were incubated with 50 µmol/L verapamil, which blocked ABCG2 activity to prevent the dye from being pumped out of cell membrane. After exposure to the dye, cells were washed with PBS and kept at 4°C before being analyzed with flow Cytometry (Moflo XDP, Beckman Coulter). We used dual-wavelength analysis to detect the proportion of SP cells.

Statistical analyses {#s2g}
--------------------

Statistical analyses were performed using the SPSS 16.0 software package. The association between clinicopathologic factors and Skp2 expression was evaluated using the Chi-square test. Survival curves were constructed using the Kaplan-Meier method, and Cox regression was used for multivariate analysis. *P* value \< 0.05 was considered statistically significant.

Results {#s3}
=======

Correlation between Skp2 expression and clinicopathologic features of nasopharyngeal carcinoma {#s3a}
----------------------------------------------------------------------------------------------

To determine if Skp2 is associated with clinicopathologic features and prognosis of NPC in South China, we used a tissue microarray containing samples from 150 patients with NPC and performed IHC to detect Skp2 expression. Samples from 23 patients dropped off the microarray and 127 could be analyzed. Of the 127 patients, 94 (74%) were men and 33 (26%) were women with a median age of 47 years old (range, 17--73). Among the cases, 4 (3.1%) were classified as Stage I; 45 (35.4%) as Stage II; 51 (40.2%) as Stage III; and 27 (21.3%) as Stage IVa. No patient had distant metastasis. The mean follow-up time was 83 months (range, 11--115), and the 5-year overall survival rate was 74.8%. The clinicopathologic features of these patients are shown in [Table 1](#cjc-30-03-204-t01){ref-type="table"}.

The IHC results showed that the positive rate of Skp2 was 75.6% in the 127 samples. Brown-yellow granules were observed in the nuclei of cells in positive samples ([Figure 1](#cjc-30-03-204-g001){ref-type="fig"}).

No association was found between Skp2 expression and any of the clinicopathologic factors, including sex, age, T stage, N stage, clinical stage, pathologic type (WHO), therapy, and the Epstain-Barr virus viral capsid antigen-IgA antibody (EBV VCA-IgA) titer ([Table 2](#cjc-30-03-204-t02){ref-type="table"}).

Prognostic significance of Skp2 expression in NPC {#s3b}
-------------------------------------------------

The correlation between Skp2 expression or clinicopathologic features and prognosis is shown in [Table 3](#cjc-30-03-204-t03){ref-type="table"}. In univariate analysis, Skp2 expression and clinicopathologic factors except age and pathologic type (WHO) could predict the overall survival (OS) or disease-free survival (DFS) ([Table 3](#cjc-30-03-204-t03){ref-type="table"}). In multivariate analysis, Skp2 expression was still significantly predictive for poor OS \[*P* = 0.009, risk ratio (RR) = 4.06\] and DFS (*P* = 0.008, RR = 3.56). In addition, clinical stages (*P* = 0.012 and RR=3.201 for OS; *P* = 0.002 and RR=1.94 for DFS) and sex (*P* = 0.016 and RR=0.31 for OS; *P* = 0.006 and RR=0.27 for DFS) were also predictive for prognosis of NPC ([Table 4](#cjc-30-03-204-t04){ref-type="table"}). Moreover, the Kaplan-Meier analysis showed that Skp2 expression in the patients with NPC could independently predict poor prognosis for both OS (*P* = 0.013) and DFS (*P* = 0.012) ([Figure 2](#cjc-30-03-204-g002){ref-type="fig"}).

Knockdown of Skp2 decreased the colony formation efficiency of NPC cells {#s3c}
------------------------------------------------------------------------

To explore the functional role of Skp2 in cell self-renewal, an important feature of CSCs, we performed a colony formation assay after transient knockdown of Skp2 in CNE-1 and CNE-2 cells. As shown in [Figure 3A](#cjc-30-03-204-g003){ref-type="fig"}, Skp2 was efficiently knocked down by siRNA in CNE-1 and CNE-2 cells. More importantly, the colony formation efficiency was dramatically decreased in these Skp2-knockdown cells (*P* = 0.001 for CNE-1 cells and *P* = 0.008 for CNE-2 cells) ([Figure 3B](#cjc-30-03-204-g003){ref-type="fig"}), suggesting that Skp2 may play a key role in the self-renewal of NPC cells.

###### Clinicopathologic features of 127 patients with nasopharyngeal carcinoma (NPC)

  Factor         No. of cases (%)           Factor           No. of cases (%)
  ------------- ------------------ ------------------------ ------------------
  Sex                                   Clinical stage      
   Male              94(74.0)                  I                 4 (3.1)
   Female            33(26.0)                 II                 45(35.4)
  Age (years)                                 III                51(40.2)
   \< 47             62(48.8)                 IVa                27(21.3)
   ≥ 47              63(49.6)       Histological type(WHO)  
  T stage                              Undifferentiated          94(74.0)
   T1                10 (7.9)           Differentiated           28(22.0)
   T2                56(44.1)              Therapy          
   T3                43(33.9)         Radiotherapy alone        107(84.3)
   T4                18(14.2)         Chemotherapy alone         1 (0.8)
  N stage                              Radiochemotherapy         19(15.0)
   N0                35(27.6)         EBV VCA-IgA titer     
   N1                48(37.8)               ≤ 1/160              38(29.9)
   N2                34(26.8)               ≥ 1/320              84(66.1)
   N3                10 (7.9)          Skp2 expression      
                                           Negative              31(24.4)
                                           Positive              96(75.6)

EBV VCA-IgA, Epstain-Barr virus viral capsid antigen-IgA antibody.

![Immunohistochemical staining of Skp2 in tumor samples from 150 patients with nasopharyngeal carcinoma (NPC). A, the NPC tissue microarray shows that 23 samples dropped off the chip and 127 were assessable. B, representative image of a Skp2-positive sample shows that many tumor cells are stained in brown-yellow (×200). C, magnification of panel B shows brown-yellow granules in the nuclei of positive tumor cells (×400). D, representative image of a Skp2-negative sample shows that no tumor cells are stained in brown-yellow (×200). E, magnification of panel D shows no brown-yellow granules in the nuclei of tumor cells (×400).](cjc-30-03-204-g001){#cjc-30-03-204-g001}

###### Association between Skp2 expression and clinicopathologic factors of 127 patients with NPC analyzed by the Chi-square test

  Clinicopathologic factor      Skp2 expression   *P* value  
  ---------------------------- ----------------- ----------- -------
  Sex                                                         0.15
   Male                               68             26      
   Female                             28              5      
  Age (Years)                                                 0.133
   \< 47                              43             19      
   ≥ 47                               51             12      
  T stage                                                     0.15
   T1                                  5              5      
   T2                                 42             14      
   T3                                 33             10      
   T4                                 16              2      
  N stage                                                     0.109
   N0                                 27              8      
   N1                                 31             17      
   N2                                 29              5      
   N3                                  9              1      
  Clinical stage                                              0.197
   I + II                             34             15      
   III + IVa                          62             16      
  Histological type(WHO)                                      0.149
   Undifferentiated                   68             26      
   Differentiated                     24              4      
  Therapy                                                     0.712
   Radiotherapy/chemotherapy          81             27      
   Radiochemotherapy                  15              4      
  EBV VCA-IgA titer                                           0.542
   ≤ 1/160                            30              8      
    ≥ 1/320                           62             22      

![Kaplan-Meier survival curves of 96 Skp2-positive and 31 Skp2-negative patients with NPC. Skp2 expression is associated with poor overall survival (A, *P* = 0.013) and disease-free survival (B, *P* = 0.012) of patients with NPC.](cjc-30-03-204-g002){#cjc-30-03-204-g002}

###### Results of univariate log--rank analysis of prognostic factors of 127 patients with NPC

  Variate                       No. of patients   OS     DFS          
  ---------------------------- ----------------- ---- ---------- ---- ----------
  Sex                                                   0.028           0.013
   Male                               94          35              39  
   Female                             33          5               5   
  Age (years)                                           0.046           0.115
   \< 47                              62          14              17  
   ≥ 47                               63          26              27  
  T stage                                               0.002          \< 0.001
   T1                                 10          2               2   
   T2                                 56          11              13  
   T3                                 43          16              17  
   T4                                 18          11              12  
  N stage                                               0.016           0.003
   N0                                 35          6               7   
   N1                                 48          14              16  
   N2                                 34          14              15  
   N3                                 10          6               6   
  Clinical stage                                       \< 0.001        \< 0.001
   I                                   4          1               1   
   II                                 45          6               8   
   III                                51          17              18  
   IVa                                27          16              17  
  Histological type (WHO)                               0.175           0.349
   Undifferentiated                   94          28              32  
   Differentiated                     28          12              12  
  Therapy                                               0.014           0.008
   Radiotherapy/chemotherapy          108         30              33  
   Radiochemotherapy                  19          10              11  
  EBV VCA--IgA                                          0.027           0.072
   ≤ 1/160                            38          7               9   
   ≥ 1/320                            84          33              34  
  Skp2 expression                                        0.02           0.018
   Negative                           31          4               5   
   Positive                           96          36              39  

OS, overall survival; DFS, disease-free survival. ^a^Events in OS include death; ^b^events in DFS include local or region relapse or distant metastasis.

Overexpression of Skp2 increased the percentage of SP cells {#s3d}
-----------------------------------------------------------

We investigated whether Skp2 could affect the percentage of SP cells using CNE-1 and CNE-2 cells. Consistent with the result of colony formation assay, overexpression of Skp2 increased the percentage of SP cells in both CNE-1 and CNE-2 cells ([Figure 4](#cjc-30-03-204-g004){ref-type="fig"}), indicating that Skp2 may be involved in the production of CSCs in NPC.

Discussion {#s4}
==========

In the present report, we show that Skp2 was highly expressed in tumor samples from the patients with NPC in South China; moreover, expression of Skp2 was an independent indicator of poor prognosis for NPC (*P* = 0.013 for OS and *P* = 0.012 for DFS). Fang *et al.*[@b16] studied NPC cases in Taiwan, another epidemic region of NPC, found that Skp2 overexpression was associated with OS and distant metastasis-free survival but not with the locoregional control. Taken together, these results suggest that Skp2 may be useful for predicting prognosis of NPC.

CSCs are a subpopulation of cancer cells that harbor stem cell characteristics like self-renewal and differentiation. CSCs have strong ability of chemoresistance[@b17]. They usually express cell membrane transporters like ABCG2 and ABCBI, which can efflux chemotherapy compounds out of cells. Furthermore, because of their capability of mobility and invasion, it is currently accepted that CSCs are responsible for metastasis[@b8],[@b17], leading to a possible correlation between CSC-like phenotype and prognosis of cancer. SP is a distinct subpopulation that has properties of stem cells and can efflux the DNA-binding dye Hoechst 33342 out of the cell membrane[@b5],[@b11],[@b12]. Previously, we determined that SP cells existed in five NPC cell lines including CNE-1 and CNE-2 (0.7% for CNE-1 and 2.6% for CNE-2), and these SP cells, like CSCs, had the ability to self-renew, proliferate, differentiate, and initiate tumorigenesis *in vivo*[@b13]. Our results using NPC cell lines show that Skp2 knockdown dramatically decreased colony formation efficiency, whereas Skp2 overexpression increased the fraction of SP cells, indicating that Skp2 may play an important role in the production or maintenance of CSCs in NPC. Furthermore, Skp2 may influence the prognosis of NPC partially by increasing the proportion of CSCs among NPC cells. This may explain our results and the results of Fang *et al*.[@b16], which show that Skp2 is associated with poor clinical outcome of NPC in South China and Taiwan, respectively.

Genomic instability triggered by deficiencies in DNA repair and apoptosis is a well-known hallmark of cancer. Skp2, an important regulator of the cell cycle, is often overexpressed in cancers. In principle, dysfunction of Skp2 may cause cell cycle abnormalities, which, in turn, increase the genomic instability of cancer cells. We recently reported that genomic instability could induce CSC production in cancer cells[@b14]. Thus, these observations provide one possible explanation for the correlation between Skp2 expression and CSC-like phenotype in NPC cells, as indicated by colony formation assay and SP cell detection assay. However, further investigation is needed to establish the key role of Skp2 in CSCs or in the development of NPC.

###### Results of multivariate Cox regression analysis of prognostic factors of 127 patients with NPC

  Variate                                 OS             DFS                         
  ----------------------------- ---------------------- ------- --------------------- -------
  Skp2 expression (positive)     4.063(1.422--11.610)   0.009   3.560(1.385--9.153)   0.008
  Clinical stage (III+IV)        3.201(1.296--7.906)    0.012   1.940(1.275--2.952)   0.002
  Sex (female)                   0.310(0.120--0.801)    0.016   0.270(0.106--0.690)   0.006
  Age (≥ 47)                              --            0.073           --             --
  Therapy (radiochemotherapy)             --            0.404           --            0.295
  VCA-IgA(≥ 1/320)                        --            0.360           --             --

RR, risk ratio; 95% CI, 95% confidence interval. "--" indicates that the risk ratio was not calculated because *P* value \> 0.05.

![Knockdown of Skp2 significantly decreases the colony formation efficiency in human NPC cells. CNE-1 and CNE-2 cells were transfected with Skp2 siRNA (siSkp2) or scrambled siRNA (NC) for 48 h. A, Western blotting shows no Skp2 expression in Skp2 siRNA-transfected cells, and no changes of Skp2 expression in scrambled siRNA-transfected cells and untransfected cells. B, the colony formation assay shows that the number of colonies is significantly lower in Skp2 siRNA-transfected cells than in scrambled siRNA-transfected cells (*P* \< 0.01).](cjc-30-03-204-g003){#cjc-30-03-204-g003}

![Overexpression of Skp2 increases the percentage of side population (SP) cells in human NPC cells. CNE-1 and CNE-2 cells were transiently transfected with pcDNA3.1-Skp2 plasmids or empty vector for 48 h. Hoechst 33342 staining was performed with or without 50 µmol/L verapamil. The percentage of SP cells significantly increased after Skp2 transfection; verapamil blocked ABCG2 activity and decreased SP cells.](cjc-30-03-204-g004){#cjc-30-03-204-g004}
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